Literature DB >> 27689195

Pre-operative Diagnosis of Pancreatic Neuroendocrine Tumors with Endoscopic Ultrasonography and Computed Tomography in a Large Series.

Raffaele Manta1, Elisabetta Nardi2, Nico Pagano3, Claudio Ricci3, Mariano Sica4, Danilo Castellani2, Helga Bertani4, Micaela Piccoli5, Barbara Mullineris5, Alberto Tringali6, Francesco Marini7, Ugo Germani7, Vincenzo Villanacci8, Riccardo Casadei3, Massimiliano Mutignani6, Rita Conigliaro4, Gabrio Bassotti2, Angelo Zullo9.   

Abstract

BACKGROUND AND AIMS: Diagnosis of pancreatic neuroendocrine tumors (p-NETs) is frequently challenging. We describe a large series of patients with p-NETs in whom both pre-operative Computed Tomography (CT) and Endoscopic Ultrasonography (EUS) were performed.
METHODS: This was a retrospective analysis of prospectively collected sporadic p-NET cases. All patients underwent both standard multidetector CT study and EUS with fine-needle aspiration (FNA). The final histological diagnosis was achieved on a post-surgical specimen. Chromogranin A (CgA) levels were measured.
RESULTS: A total of 80 patients (mean age: 58 +/- 14.2 years; males: 42) were enrolled. The diameter of functioning was significantly lower than that of non-functioning p-NETs (11.2 +/- 8.5 mm vs 19.8 +/- 12.2 mm; P = 0.0004). The CgA levels were more frequently elevated in non-functioning than functioning pNET patients (71.4% vs 46.9%; P = 0.049). Overall, the CT study detected the lesion in 51 (63.7%) cases, being negative in 26 (68.4%) patients with a tumor </=10 mm, and in a further 3 (15%) cases with a tumor diameter </=20 mm. CT overlooked the pancreatic lesion more frequently in patients with functioning than non-functioning p-NETs (46.5% vs 24.3%; P = 0.002). EUS allowed a more precise pre-operative tumor measurement, with an overall incorrect dimension in only 9 (11.2%) patients. Of note, the EUS-guided FNA suspected the neuroendocrine nature of tumor in all cases.
CONCLUSIONS: Data of this large case series would suggest that the EUS should be included in the diagnostic work-up in all patients with a suspected p-NET, even when the CT study was negative for a primary lesion in the pancreas.

Entities:  

Mesh:

Year:  2016        PMID: 27689195     DOI: 10.15403/jgld.2014.1121.253.ned

Source DB:  PubMed          Journal:  J Gastrointestin Liver Dis        ISSN: 1841-8724            Impact factor:   2.008


  9 in total

Review 1.  Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2018-07-17       Impact factor: 4.512

2.  Indications for resection and perioperative outcomes of surgery for pancreatic neuroendocrine neoplasms in Germany: an analysis of the prospective DGAV StuDoQ|Pancreas registry.

Authors:  Ioannis Mintziras; Tobias Keck; Jens Werner; Stefan Fichtner-Feigl; Uwe Wittel; Norbert Senninger; Thorsten Vowinkel; Jörg Köninger; Matthias Anthuber; Bernd Geißler; Detlef Klaus Bartsch
Journal:  Surg Today       Date:  2019-06-25       Impact factor: 2.549

Review 3.  Current updates and future directions in diagnosis and management of gastroenteropancreatic neuroendocrine neoplasms.

Authors:  Andrew Canakis; Linda S Lee
Journal:  World J Gastrointest Endosc       Date:  2022-05-16

4.  Evolving role of the endoscopist in management of gastrointestinal neuroendocrine tumors.

Authors:  Cemal Yazici; Brian R Boulay
Journal:  World J Gastroenterol       Date:  2017-07-21       Impact factor: 5.742

Review 5.  Pancreatic neuroendocrine tumors: the basics, the gray zone, and the target.

Authors:  Dionysia Kelgiorgi; Christos Dervenis
Journal:  F1000Res       Date:  2017-05-10

Review 6.  An update on the diagnosis of gastroenteropancreatic neuroendocrine neoplasms.

Authors:  Jiayun M Fang; Jay Li; Jiaqi Shi
Journal:  World J Gastroenterol       Date:  2022-03-14       Impact factor: 5.374

7.  Endoscopic techniques for diagnosis and treatment of gastro-entero-pancreatic neuroendocrine neoplasms: Where we are.

Authors:  Roberta Elisa Rossi; Alessandra Elvevi; Camilla Gallo; Andrea Palermo; Pietro Invernizzi; Sara Massironi
Journal:  World J Gastroenterol       Date:  2022-07-14       Impact factor: 5.374

8.  Limited role of Chromogranin A as clinical biomarker for pancreatic neuroendocrine tumors.

Authors:  Alessandra Pulvirenti; Deepthi Rao; Caitlin A Mcintyre; Mithat Gonen; Laura H Tang; David S Klimstra; Martin Fleisher; Lakshmi V Ramanathan; Diane Reidy-Lagunes; Peter J Allen
Journal:  HPB (Oxford)       Date:  2018-10-23       Impact factor: 3.647

9.  Assessment of pancreatic neuroendocrine tumor cytologic genotype diversity to guide personalized medicine using a custom gastroenteropancreatic next-generation sequencing panel.

Authors:  Ferga C Gleeson; Jesse S Voss; Benjamin R Kipp; Sarah E Kerr; John S Van Arnam; John R Mills; Cherisse A Marcou; Amber R Schneider; Zheng Jin Tu; Michael R Henry; Michael J Levy
Journal:  Oncotarget       Date:  2017-06-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.